QXAS yields 25.02% · JNJ yields 2.13%● Live data
📍 QXAS pulled ahead of the other in Year 1
Combined, QXAS + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of QXAS + JNJ for your $10,000?
QXAS seeks 2x daily exposure to the largest crypto assets, excluding Bitcoin (BTC), stablecoins, and memecoins. It does not hold crypto directly, but gains exposure via swaps, options, futures contracts, or ETPs, targeting up to 10 crypto assets traded in US exchanges. The fund uses options contracts for leveraged exposure, allowing dynamic adjustments based on market conditions, liquidity, or pricing. The fund buys standardized, cash-settled futures to manage contango and backwardation and invests in ETPs for long exposure. The fund holds cash and cash-like instruments as collateral and may enter reverse repurchase agreements. Up to 25% of assets may be invested through a wholly owned Cayman Islands subsidiary. The market cap-weighted portfolio is reviewed and rebalanced at least monthly, capping each asset at 50%. The actively managed fund has full discretion to adjust at any time. Daily leverage resets may cause long-term returns to differ from the underlying assets.
Full QXAS Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.